|
|
Post by lennymnkd on Mar 24, 2023 16:19:19 GMT -5
Effortlessly see your glucose levels and where they’re headed, so you can make smarter decisions about food and activity in the moment to take better control of your diabetes.
DEXCOM CGM
|
|
|
|
Post by radgray68 on Mar 24, 2023 19:37:03 GMT -5
Any chance BlueHale could be polished up and sold for enough to put a dent in our debt?
I know almost nothing about how they will capitalize on BlueHale's technology. Other than to measure our own pt.'s dosing, would others rent the technology from us? Guess I'm not being too creative but still, how can we make any serious money from it?
|
|
|
|
Post by prcgorman2 on Mar 24, 2023 20:12:24 GMT -5
"Sharing the data would require patient consent - I know a lot of diabetics (me amongst them) who refuse to let their data be shared. I will share very specifically, but not an open ended agreement like any doctor they chose."
Well, lets look again what Mike said, "...and the patients can share with their doctors and their caregivers..."
Don't try to read into this too much agedhippie . Mike shares your concerns, too. Nobody will lose any control over their data and this is a non-issue once PWDs are provided with the details and how it is designed to fully integrate with the CGM to their advantage. "I think, but am not certain, that if they do that integration the app needs FDA approval because it would be a medical device."Does FDA approval pose some sort of problem? MNKD lives in a regulatory environment and I'm pretty sure they don't see it as any sort of issue. Besides, it's likely they received some sort of feedback or guidance from the FDA very early on, even though nobody really knows if it's a "thing" or just a formed imaginary guess that we so often see posted. I like the idea of the integration as it makes dosing a lot simpler if it's properly integrated. It's more complex than it seems because simply recording when you took a dose is not terribly useful IMHO because you want to know what the future looks like as the CGM tells you what's happening right now. This means you need to generate a predictive curve and that's the bit that gets the FDA worked up. For some reason (I have no idea why) the FDA really doesn't like bolus assistants and has blocked them from meters in the US - it's deeply annoying. Generally though I think this is a good idea. In an ideal world I would say integrate it into xDrip+ because that will get a lot of visibility amongst early adopters. I think agedhippie gave good clues to highly regulated security-senstive privacy-focused systems development complexity for distributed mobile applications. The mobile app needs to be able to interface with various health IT providers to achieve much useful coverage with doctors, and clinics (and hospitals?). And the mobile users are spread across a diverse set of mobile device capabilities and two main operating systems. i.e., Android and Apple. And sometimes marketing people want to be able to update the public and their customers. Let’s hope the important development started two years ago.  |
|
|
|
Post by agedhippie on Mar 24, 2023 21:59:06 GMT -5
Effortlessly see your glucose levels and where they’re headed, so you can make smarter decisions about food and activity in the moment to take better control of your diabetes. DEXCOM CGM That page is really interesting. Notice that the focus was entirely on managing diabetes and nowhere, other that the disclaimers around connected insulin pumps, did it mention any type of treatment for diabetes; insulin, GLP-1, metformin, or even diet and exercise. |
|
|
|
Post by sayhey24 on Mar 25, 2023 6:52:41 GMT -5
Any chance BlueHale could be polished up and sold for enough to put a dent in our debt? I know almost nothing about how they will capitalize on BlueHale's technology. Other than to measure our own pt.'s dosing, would others rent the technology from us? Guess I'm not being too creative but still, how can we make any serious money from it? I think BluHale may add to the debt but I can never see it being a consumer product. I see it being used for in office patient training and as Mike said during studies. The Dexcom API as Mike has said is publicly available - developer.dexcom.com/homeDexcom wants to sell CGMs. If afrezza can help sell them and we know it can at least in the Medicare space Kevin Sayer will be interested in supporting MNKD's efforts with BluHale but a simple UI button on a phone app to answer the question what size did you take small, medium, or large would provide a similar capability. It may not be as techno-flashy but would be good enough. If it can help in any trials, great. As a money maker, I don't see it. |
|
|
|
Post by sayhey24 on Mar 25, 2023 6:56:55 GMT -5
Effortlessly see your glucose levels and where they’re headed, so you can make smarter decisions about food and activity in the moment to take better control of your diabetes. DEXCOM CGM That page is really interesting. Notice that the focus was entirely on managing diabetes and nowhere, other that the disclaimers around connected insulin pumps, did it mention any type of treatment for diabetes; insulin, GLP-1, metformin, or even diet and exercise. Why is that interesting? We know Dexcom wants to sell CGMs. Aside from needing insulin treated patients for Medicare payment they want to sell to everyone including Wegovy users which may become a big market. |
|
|
|
Post by prcgorman2 on Mar 25, 2023 8:04:12 GMT -5
Any chance BlueHale could be polished up and sold for enough to put a dent in our debt? I know almost nothing about how they will capitalize on BlueHale's technology. Other than to measure our own pt.'s dosing, would others rent the technology from us? Guess I'm not being too creative but still, how can we make any serious money from it? I think BluHale may add to the debt but I can never see it being a consumer product. I see it being used for in office patient training and as Mike said during studies. The Dexcom API as Mike has said is publicly available - developer.dexcom.com/homeDexcom wants to sell CGMs. If afrezza can help sell them and we know it can at least in the Medicare space Kevin Sayer will be interested in supporting MNKD's efforts with BluHale but a simple UI button on a phone app to answer the question what size did you take small, medium, or large would provide a similar capability. It may not be as techno-flashy but would be good enough. If it can help in any trials, great. As a money maker, I don't see it. Agree. Ironically, it is called BlueHale which implies exphiration, not inspiration. Make the little bugger capable of reading BG on exhale and dose reading on inhale, and it could be a lot more interesting to consumers. |
|
|
|
Post by hopingandwilling on Mar 25, 2023 9:03:07 GMT -5
Sey, With MannKind tomorrow never arrives for their pandering with false hope with the Bluhaler. Seems like only yesterday they made this promise, but it was four years ago--wonder what happened to this one.
WESTLAKE VILLAGE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) and One Drop today announced that they have signed a collaborative agreement that is intended to integrate MannKind’s BluHale® accessory device into the One Drop platform. BluHale is a Bluetooth-connected accessory that attaches to the Afrezza® inhaler and is designed to convey real-time information about inhalation effort and insulin dose. The goal of this collaboration is to provide a seamless experience for Afrezza patients, including automatic tracking of their insulin doses as well as other important health information on the One Drop platform. The agreement is expected to bring One Drop’s award winning user experience to Afrezza users, empowering them with AI-enabled glucose forecasts, predictive insights, and the opportunity to connect one-on-one with One Drop’s certified diabetes educators, an educational service that has been recognized by the American Diabetes Association.
|
|
|
|
Post by hellodolly on Mar 25, 2023 9:18:34 GMT -5
Sey, With MannKind tomorrow never arrives for their pandering with false hope with the Bluhaler. Seems like only yesterday they made this promise, but it was four years ago--wonder what happened to this one. WESTLAKE VILLAGE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) and One Drop today announced that they have signed a collaborative agreement that is intended to integrate MannKind’s BluHale® accessory device into the One Drop platform. BluHale is a Bluetooth-connected accessory that attaches to the Afrezza® inhaler and is designed to convey real-time information about inhalation effort and insulin dose. The goal of this collaboration is to provide a seamless experience for Afrezza patients, including automatic tracking of their insulin doses as well as other important health information on the One Drop platform. The agreement is expected to bring One Drop’s award winning user experience to Afrezza users, empowering them with AI-enabled glucose forecasts, predictive insights, and the opportunity to connect one-on-one with One Drop’s certified diabetes educators, an educational service that has been recognized by the American Diabetes Association.
Says it all right there. Breaking a cardinal rule of investing, "Invest with your mind and not your emotions" but, love the double entendre's in this, " tomorrow never arrives" & " false hope". |
|
|
|
Post by letitride on Mar 25, 2023 9:29:55 GMT -5
That should have been saved for stock twits it would be much more fitting there.
|
|
|
|
Post by agedhippie on Mar 25, 2023 9:39:46 GMT -5
That page is really interesting. Notice that the focus was entirely on managing diabetes and nowhere, other that the disclaimers around connected insulin pumps, did it mention any type of treatment for diabetes; insulin, GLP-1, metformin, or even diet and exercise. Why is that interesting? We know Dexcom wants to sell CGMs. Aside from needing insulin treated patients for Medicare payment they want to sell to everyone including Wegovy users which may become a big market. It's interesting because traditionally their page has focused on T1 diabetics - insulin users. The current page has broadened that to all diabetics. This is their messaging about CGMs not just being for insulin users. |
|
|
|
Post by agedhippie on Mar 25, 2023 9:50:18 GMT -5
Agree. Ironically, it is called BlueHale which implies exphiration, not inspiration. Make the little bugger capable of reading BG on exhale and dose reading on inhale, and it could be a lot more interesting to consumers. That would be really nice, but technically challenging. I think it's enough that it registers thata dose is taken. You can see an analogy on the insulin pen side in InPen from Medtronics, and the Unity system from Bigfoot which connect the insulin pen over bluetooth. Interestingly my insurer will cover InPen as of this year. The point of these systems is that they overcome the longstanding issue of people not recording their insulin bolus. Doctors would dearly like to have the time and dose information. Trial data says that connected systems reduce HbA1c. |
|
|
|
Post by lennymnkd on Mar 25, 2023 10:35:38 GMT -5
Why is that interesting? We know Dexcom wants to sell CGMs. Aside from needing insulin treated patients for Medicare payment they want to sell to everyone including Wegovy users which may become a big market. It's interesting because traditionally their page has focused on T1 diabetics - insulin users. The current page has broadened that to all diabetics. This is their messaging about CGMs not just being for insulin users. Wasn’t there something we posted a short while back for athletes using it as well .. maybe for just good overall health.. like a Apple Watch. Maybe there is more to this then we see .. these guys are visionary’s.. |
|
|
|
Post by prcgorman2 on Mar 25, 2023 12:37:06 GMT -5
Agree. Ironically, it is called BlueHale which implies exphiration, not inspiration. Make the little bugger capable of reading BG on exhale and dose reading on inhale, and it could be a lot more interesting to consumers. That would be really nice, but technically challenging. I think it's enough that it registers thata dose is taken. You can see an analogy on the insulin pen side in InPen from Medtronics, and the Unity system from Bigfoot which connect the insulin pen over bluetooth. Interestingly my insurer will cover InPen as of this year. The point of these systems is that they overcome the longstanding issue of people not recording their insulin bolus. Doctors would dearly like to have the time and dose information. Trial data says that connected systems reduce HbA1c. We discussed breath-powered CGM functionality before, and someone posted a link to research (in Omaha, Nebraska? Berkshire-Hathaway?) on a breath-powered device. One of the reason I suspect it’s possible is a story I read where drug-sniffing dogs were trained to smell low blood glucose on very young T1s, especially while sleeping. I’ve assumed the accuracy of breath-powered CGMs might be poor, but would five levels such as 1) very low, 2) low, 3) adequate, 4) high, and 5) very high, be achievable and sufficient? Or even 3 levels? |
|
sky
Lab Rat
Posts: 46 
Sentiment: Long
|
Post by sky on Mar 25, 2023 14:46:17 GMT -5
visionary’s..
i like that,.MNKD only hope.
i said it dont shoot.
|
|
